-
Je něco špatně v tomto záznamu ?
Modulatory Effect of the Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen on Circulating Immune Cells in Systemic Lupus Erythematosus
G. Gabcova, P. Horak, Z. Mikulkova, M. Skacelova, S. Zehnalova, A. Smrzova, A. Petrackova, F. Mrazek, E. Kriegova,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
FNOL
Ministerstvo Zdravotnictví České Republiky
00098892
Ministerstvo Zdravotnictví České Republiky
IGA_LF_2019_006
Univerzita Palackého v Olomouci
IGA_LF_2019_014
Univerzita Palackého v Olomouci
- MeSH
- cyklofosfamid terapeutické užití MeSH
- dospělí MeSH
- imunologická paměť MeSH
- imunomodulace MeSH
- imunosupresiva terapeutické užití MeSH
- indukce remise MeSH
- intravenózní podání MeSH
- klinické protokoly MeSH
- kohortové studie MeSH
- krevní oběh MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfocyty účinky léků imunologie MeSH
- mladý dospělý MeSH
- nefritida při lupus erythematodes farmakoterapie MeSH
- průtoková cytometrie MeSH
- systémový lupus erythematodes farmakoterapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
A Euro-Lupus regimen of low-dose intravenous cyclophosphamide (CFA) is commonly used to treat severe organ manifestations of systemic lupus erythematosus (SLE), particularly lupus nephritis (LN). There are no data on the distributions and dynamics of immune cell populations in patients with various treatment outcomes. The circulating immune cells of 11 female SLE patients were assessed before and after Euro-Lupus regimen (cumulative dose of 3000 mg CFA) by flow cytometry together with those of 16 healthy women. A subanalysis was performed in LN patients who achieved complete remission (CR; n = 3), partial remission (PR; n = 4), and no response (NR; n = 2). In SLE, the Euro-Lupus regimen decreased the percentage and absolute count of B cells; increased the percentage of CD8+ T cells, T regulatory cells, neutrophils, and monocyte subsets; and activated T and NK cells compared to healthy controls (P < 0.050). Patients with LN achieving CR had significantly lower proportions of CD27+ B memory cells compared to poor responders (PR/NR, P = 0.035). The post-treatment percentages and absolute numbers of B cells, T cells, NK cells, monocytes, and neutrophils showed high inter-individual variability with no association with treatment outcome. Our pilot study revealed the dynamics of changes in immune cell populations in SLE patients during a Euro-Lupus regimen, mainly the lowering of B cells. In LN patients who achieved CR, a lower proportion of CD27+ B memory cells was evident compared to poor responders (PR/NR). Further studies on usefulness of monitoring immune cells for treatment response prediction on larger cohorts are needed.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005789
- 003
- CZ-PrNML
- 005
- 20200526095724.0
- 007
- ta
- 008
- 200511s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00005-019-00563-4 $2 doi
- 035 __
- $a (PubMed)31620814
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Gabcova, Gabriela $u Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc, University Hospital Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic.
- 245 10
- $a Modulatory Effect of the Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen on Circulating Immune Cells in Systemic Lupus Erythematosus / $c G. Gabcova, P. Horak, Z. Mikulkova, M. Skacelova, S. Zehnalova, A. Smrzova, A. Petrackova, F. Mrazek, E. Kriegova,
- 520 9_
- $a A Euro-Lupus regimen of low-dose intravenous cyclophosphamide (CFA) is commonly used to treat severe organ manifestations of systemic lupus erythematosus (SLE), particularly lupus nephritis (LN). There are no data on the distributions and dynamics of immune cell populations in patients with various treatment outcomes. The circulating immune cells of 11 female SLE patients were assessed before and after Euro-Lupus regimen (cumulative dose of 3000 mg CFA) by flow cytometry together with those of 16 healthy women. A subanalysis was performed in LN patients who achieved complete remission (CR; n = 3), partial remission (PR; n = 4), and no response (NR; n = 2). In SLE, the Euro-Lupus regimen decreased the percentage and absolute count of B cells; increased the percentage of CD8+ T cells, T regulatory cells, neutrophils, and monocyte subsets; and activated T and NK cells compared to healthy controls (P < 0.050). Patients with LN achieving CR had significantly lower proportions of CD27+ B memory cells compared to poor responders (PR/NR, P = 0.035). The post-treatment percentages and absolute numbers of B cells, T cells, NK cells, monocytes, and neutrophils showed high inter-individual variability with no association with treatment outcome. Our pilot study revealed the dynamics of changes in immune cell populations in SLE patients during a Euro-Lupus regimen, mainly the lowering of B cells. In LN patients who achieved CR, a lower proportion of CD27+ B memory cells was evident compared to poor responders (PR/NR). Further studies on usefulness of monitoring immune cells for treatment response prediction on larger cohorts are needed.
- 650 _2
- $a intravenózní podání $7 D061605
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a krevní oběh $7 D001775
- 650 _2
- $a klinické protokoly $7 D002985
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a cyklofosfamid $x terapeutické užití $7 D003520
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologická paměť $7 D007156
- 650 _2
- $a imunomodulace $7 D056747
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a systémový lupus erythematodes $x farmakoterapie $7 D008180
- 650 _2
- $a nefritida při lupus erythematodes $x farmakoterapie $7 D008181
- 650 _2
- $a lymfocyty $x účinky léků $x imunologie $7 D008214
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Horak, Pavel $u Department of Internal Medicine III-Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacký University Olomouc, University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Mikulkova, Zuzana $u Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc, University Hospital Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic.
- 700 1_
- $a Skacelova, Martina $u Department of Internal Medicine III-Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacký University Olomouc, University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Zehnalova, Sarka $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Smrzova, Andrea $u Department of Internal Medicine III-Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Palacký University Olomouc, University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Petrackova, Anna $u Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc, University Hospital Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic.
- 700 1_
- $a Mrazek, Frantisek $u Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc, University Hospital Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic.
- 700 1_
- $a Kriegova, Eva $u Department of Immunology, Faculty of Medicine and Dentistry, Palacký University Olomouc, University Hospital Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic. eva.kriegova@email.cz.
- 773 0_
- $w MED00000581 $t Archivum immunologiae et therapiae experimentalis $x 1661-4917 $g Roč. 67, č. 6 (2019), s. 415-425
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31620814 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200526095720 $b ABA008
- 999 __
- $a ok $b bmc $g 1524647 $s 1095845
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 67 $c 6 $d 415-425 $e 20191016 $i 1661-4917 $m Archivum Immunologiae et Therapiae Experimentalis $n Arch Immunol Ther Exp (Warsz) $x MED00000581
- GRA __
- $a FNOL $p Ministerstvo Zdravotnictví České Republiky
- GRA __
- $a 00098892 $p Ministerstvo Zdravotnictví České Republiky
- GRA __
- $a IGA_LF_2019_006 $p Univerzita Palackého v Olomouci
- GRA __
- $a IGA_LF_2019_014 $p Univerzita Palackého v Olomouci
- LZP __
- $a Pubmed-20200511